Stacey Melquist, Phd. - Background in Neurodegeneration*
Nov 1, 2016 9:34:58 GMT -5
qbeing1010 and wayne14072 like this
Post by buffettlike on Nov 1, 2016 9:34:58 GMT -5
American Heart Association's Scientific Sessions 2016 - New Orleans, November 12-16, 2016
November 14, 10:40 a.m. CST - Stacey Melquist, Ph.D., Arrowhead senior scientist will deliver an oral presentation titled, "Targeting factor XII (F12) with a novel RNAi delivery platform as a prophylactic treatment for thromboembolism"
November 14, 2:00 p.m. CST - Stacey Melquist, Ph.D., Arrowhead senior scientist will deliver an oral presentation titled, "Targeting apolipoprotein(a) with a novel RNAi delivery platform as a prophylactic treatment to reduce risk of cardiovascular events in individuals with elevated lipoprotein (a)"
Wikipedia:
*Neurodegeneration is the umbrella term for the progressive loss of structure or function of neurons, including death of neurons. Many neurodegenerative diseases including amyotrophic lateral sclerosis, Parkinson's, Alzheimer's, and Huntington's occur as a result of neurodegenerative processes. Such diseases are incurable, resulting in progressive degeneration and/or death of neuron cells.[1] As research progresses, many similarities appear that relate these diseases to one another on a sub-cellular level. Discovering these similarities offers hope for therapeutic advances that could ameliorate many diseases simultaneously. There are many parallels between different neurodegenerative disorders including atypical protein assemblies as well as induced cell death.[2][3] Neurodegeneration can be found in many different levels of neuronal circuitry ranging from molecular to systemic.
LinkedIn:
Senior Scientist III
Arrowhead Pharmaceuticals
May 2014 – Present (2 years 7 months)Madison Area, Wisconsin
Lead the biology effort towards development of RNAi therapeutics towards liver targets.
Associate Principal Scientist
Merck
February 2012 – December 2013 (1 year 11 months)
Led the biology effort for a neuroscience imaging program to support Alzheimer’s Disease target (AD). Provided pharmacologic support for multiple neuroscience targets, including the development and technical support on both binding and cell-based functional assays.
• Delivered program to stage gate three months ahead of schedule.
• Developed novel plate-based radioligand binding assay with AD tissue homogenates thus giving the team a competitive advantage.
• Provided guidance and technical support in developing a label-free mass spectrometry approach in AD brain homogenates to prioritize potential ligands for radiolabeling.
• Provided guidance and technical support in development of a novel cell-based protein uptake assays.
• Developed relationships with external partners to collaborate on programs, as well as to obtain additional neurodegenerative disease tissues to evaluate potential for binding internally-derived
Senior Research Fellow
Mayo Clinic College of Medicine
October 2002 – September 2007 (5 years)Jacksonville, Florida Area
Genetics of Alzheimer's Disease (AD) and other Neurodegenerative Disorders. Focused on using both population genetic and familial genetic approaches to identify additional genes involved in neurodegenerative disease process.
• Coordinated with clinicians on biological sample collection and genetic material evaluations.
• Initiated and maintained a new collaboration with clinical group at the Norwegian University of Science and Technology in Trondheim, Norway to collect and evaluate biological samples from patients to identify both novel genetic risk factors and biomarkers for AD
• Led and provided technical support for Genome Wide Association study of pathologically confirmed Progressive Supranuclear Palsy (PSP) patients and controls that identified a novel genetic risk factor.
• Performed linkage analysis & follow up sequencing in neurodegenerative disease families to determine locations and specific defects in genes involved in neurodegenerative disease.
November 14, 10:40 a.m. CST - Stacey Melquist, Ph.D., Arrowhead senior scientist will deliver an oral presentation titled, "Targeting factor XII (F12) with a novel RNAi delivery platform as a prophylactic treatment for thromboembolism"
November 14, 2:00 p.m. CST - Stacey Melquist, Ph.D., Arrowhead senior scientist will deliver an oral presentation titled, "Targeting apolipoprotein(a) with a novel RNAi delivery platform as a prophylactic treatment to reduce risk of cardiovascular events in individuals with elevated lipoprotein (a)"
Wikipedia:
*Neurodegeneration is the umbrella term for the progressive loss of structure or function of neurons, including death of neurons. Many neurodegenerative diseases including amyotrophic lateral sclerosis, Parkinson's, Alzheimer's, and Huntington's occur as a result of neurodegenerative processes. Such diseases are incurable, resulting in progressive degeneration and/or death of neuron cells.[1] As research progresses, many similarities appear that relate these diseases to one another on a sub-cellular level. Discovering these similarities offers hope for therapeutic advances that could ameliorate many diseases simultaneously. There are many parallels between different neurodegenerative disorders including atypical protein assemblies as well as induced cell death.[2][3] Neurodegeneration can be found in many different levels of neuronal circuitry ranging from molecular to systemic.
LinkedIn:
Senior Scientist III
Arrowhead Pharmaceuticals
May 2014 – Present (2 years 7 months)Madison Area, Wisconsin
Lead the biology effort towards development of RNAi therapeutics towards liver targets.
Associate Principal Scientist
Merck
February 2012 – December 2013 (1 year 11 months)
Led the biology effort for a neuroscience imaging program to support Alzheimer’s Disease target (AD). Provided pharmacologic support for multiple neuroscience targets, including the development and technical support on both binding and cell-based functional assays.
• Delivered program to stage gate three months ahead of schedule.
• Developed novel plate-based radioligand binding assay with AD tissue homogenates thus giving the team a competitive advantage.
• Provided guidance and technical support in developing a label-free mass spectrometry approach in AD brain homogenates to prioritize potential ligands for radiolabeling.
• Provided guidance and technical support in development of a novel cell-based protein uptake assays.
• Developed relationships with external partners to collaborate on programs, as well as to obtain additional neurodegenerative disease tissues to evaluate potential for binding internally-derived
Senior Research Fellow
Mayo Clinic College of Medicine
October 2002 – September 2007 (5 years)Jacksonville, Florida Area
Genetics of Alzheimer's Disease (AD) and other Neurodegenerative Disorders. Focused on using both population genetic and familial genetic approaches to identify additional genes involved in neurodegenerative disease process.
• Coordinated with clinicians on biological sample collection and genetic material evaluations.
• Initiated and maintained a new collaboration with clinical group at the Norwegian University of Science and Technology in Trondheim, Norway to collect and evaluate biological samples from patients to identify both novel genetic risk factors and biomarkers for AD
• Led and provided technical support for Genome Wide Association study of pathologically confirmed Progressive Supranuclear Palsy (PSP) patients and controls that identified a novel genetic risk factor.
• Performed linkage analysis & follow up sequencing in neurodegenerative disease families to determine locations and specific defects in genes involved in neurodegenerative disease.